BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

CHMP, BRUKINSA

More Like This

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025